Literature DB >> 8437501

[Malignant adrenal pheochromocytoma--problems in evaluating clinical diagnosis and morphologic extent].

M Brückner1, B C Padberg, M Dürig, S Schröder.   

Abstract

Reports on three patients with malignant adrenal phaeochromocytoma are used as a basis for discussion of involved in diagnosing functionally inactive paragangliomas and in discriminating between benign and malignant adrenomedullary tumours. Malignancy can so far only be ascertained in such neoplasms by evidence of metastatic growth. Our findings, however, show that increased tumour weight (more than 200 g), high mitotic activity (more than 5 mitoses per HPF) and loss of S-100 protein-positive subtentacular cells make it possible to distinguish high-risk cases (with increased risk of recurrence and metastasis).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437501     DOI: 10.1007/bf00207993

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  19 in total

1.  Urinary excretion of catecholamines and their metabolites in pheochromocytoma.

Authors:  J R CROUT; J J PISANO; A SJOERDSMA
Journal:  Am Heart J       Date:  1961-03       Impact factor: 4.749

2.  Long-term results in 64 patients operated upon for pheochromocytoma.

Authors:  G Stenström; I Ernest; L E Tisell
Journal:  Acta Med Scand       Date:  1988

3.  Adrenomedullary hyperplasia and phaeochromocytoma. DNA cytophotometric findings in 47 cases.

Authors:  B C Padberg; E Garbe; E Achilles; H Dralle; M Bressel; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

4.  Immunocytochemistry of paragangliomas--value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis.

Authors:  E Achilles; B C Padberg; K Holl; G Klöppel; S Schröder
Journal:  Histopathology       Date:  1991-05       Impact factor: 5.087

5.  Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.

Authors:  L J Helman; P S Cohen; S D Averbuch; M J Cooper; H R Keiser; M A Israel
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

6.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

7.  Diagnosis, localization, and management of pheochromocytoma. Pitfalls and follow-up in 41 patients.

Authors:  N A Samaan; R C Hickey; P E Shutts
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

8.  Advances in the diagnosis and treatment of pheochromocytoma.

Authors:  R J Havlik; C E Cahow; B K Kinder
Journal:  Arch Surg       Date:  1988-05

9.  The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981.

Authors:  G S Andersen; D B Toftdahl; J O Lund; S Strandgaard; P E Nielsen
Journal:  J Hum Hypertens       Date:  1988-10       Impact factor: 3.012

10.  The biochemical diagnosis, localization and follow up of phaeochromocytoma: the role of plasma and urinary catecholamine measurements.

Authors:  D H Jones; J L Reid; C A Hamilton; D J Allison; R B Welbourn; C T Dollery
Journal:  Q J Med       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.